Veru Inc. Announces Conference Call for Fiscal Year 2025 Results
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company specializing in developing innovative treatments for cardiometabolic and inflammatory diseases, has exciting updates regarding its upcoming financial results presentation. The company will host a conference call and audio webcast to discuss its fiscal year 2025 financial results and provide an overview of its business developments.
Details of the Conference Call
This conference call is scheduled for December 17, 2025, at 8:00 a.m. ET. Interested parties can access the audio webcast through Veru's official website, where updates and announcements are regularly posted. For those wishing to participate via telephone, they can dial the domestic number 1-800-341-1602 or the international number 1-412-902-6706 to join the call live.
Understanding Veru Inc.'s Innovative Approach
Veru Inc. focuses on creating state-of-the-art medical solutions within the biopharmaceutical sector. Among its key developments are two promising drug candidates—enobosarm and sabizabulin. Enobosarm, categorized as a selective androgen receptor modulator (SARM), is being optimized to work synergistically with GLP-1 receptor agonists (RAs) to enable more efficient and selective weight reduction. This combination therapy aims for improved body composition by reducing fat while preserving lean muscle mass.
The Significance of Enobosarm in Weight Management
In a recent phase 2b clinical trial named QUALITY, Veru evaluated the efficacy of enobosarm in older adults undergoing treatment with semaglutide, a well-known GLP-1 RA. The results indicated that participants who received enobosarm alongside GLP-1 therapies experienced superior fat loss while preserving their muscle mass, contributing to enhanced physical functioning. This approach laid the groundwork for future investigations into enobosarm's potential to facilitate better outcomes in weight management.
Future Clinical Trials: PLATEAU Study
Looking ahead, Veru is gearing up for its Phase 2b PLATEAU clinical study, which will further extend the understanding of enobosarm’s capabilities in supporting weight reduction among patients characterized by obesity (BMI ? 35). This pivotal study aims to measure various outcomes, including total body weight and physical function over 72 weeks. Importantly, interim analyses will be conducted at the 36-week mark to evaluate changes in body composition metrics.
Objectives of the PLATEAU Clinical Study
The PLATEAU study seeks to ascertain whether treatment with enobosarm can effectively address challenges faced by patients who hit weight loss plateaus while on GLP-1 RA therapy. By focusing on both weight management and the preservation of functional muscle mass, this research will contribute valuable insights for the future of obesity treatment protocols.
Contacting Veru’s Investor Relations
For those interested in learning more about Veru Inc.'s strategies and prospects, the company encourages outreach to its Investor Relations team. Samuel Fisch, the Executive Director of Investor Relations and Corporate Communications, is available for any inquiries via email at veruinvestor@verupharma.com. This direct line of communication ensures that stakeholders remain informed about the company’s developments.
Frequently Asked Questions
What is the focus of Veru Inc.'s drug development?
Veru Inc. specializes in developing innovative medicines aimed at treating cardiometabolic and inflammatory diseases.
When is the next conference call scheduled?
The conference call will take place on December 17, 2025, at 8:00 a.m. ET.
What treatments are included in Veru's pipeline?
Veru's pipeline includes enobosarm, a selective androgen receptor modulator, and sabizabulin, aimed at targeting atherosclerosis.
How can I access the conference call?
You can access the call by dialing 1-800-341-1602 domestically or 1-412-902-6706 internationally.
Who can I contact for more information about Veru Inc.?
For further inquiries, you can reach out to Samuel Fisch at veruinvestor@verupharma.com.
